We are live on
!
Find out more
Chevy Chase Trust Portfolio holdings
AUM
$34.7B
1-Year Est. Return
29.45%
This Fund
S&P 500
This Quarter
Est. Return
+10.58%
1 Year Est. Return
+29.45%
3 Year Est. Return
+102.04%
5 Year Est. Return
+142.29%
10 Year Est. Return
+523.99%
AUM
$25.3B
AUM Growth
+$1.74B
(+7.4%)
Cap. Flow
+$21M
Cap. Flow
% of AUM
0.08%
Top 10 Holdings %
Top 10 Hldgs %
27.19%
Holding
664
New
7
Increased
437
Reduced
146
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$36.8M |
| 2 |
Johnson & Johnson
JNJ
|
+$27.6M |
| 3 |
Walt Disney
DIS
|
+$20.5M |
| 4 |
Verizon
VZ
|
+$20.4M |
| 5 |
ABB
ABB Ltd
ABB
|
+$19.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$32.7M |
| 2 |
CVS Health
CVS
|
+$29.4M |
| 3 |
Novartis
NVS
|
+$23.7M |
| 4 |
Nasdaq
NDAQ
|
+$21.3M |
| 5 |
EOG Resources
EOG
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.67% |
| 2 | Healthcare | 14.27% |
| 3 | Financials | 12.53% |
| 4 | Consumer Discretionary | 9.36% |
| 5 | Communication Services | 7.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Bio-Rad Laboratories Class A
BIO
$8.71B
| $5.99M | 0.02% |
12,512
+127
| +1% | +$59.5K |
|
477
Charles River Laboratories
CRL
$11.2B
| $5.97M | 0.02% |
29,567
+303
| +1% | +$68.7K |
|
478
Tapestry
TPR
$30.8B
| $5.91M | 0.02% |
137,189
-1,403
| -1% | -$60.2K |
|
479
Qorvo
QRVO
$7.99B
| $5.91M | 0.02% |
58,224
-367
| -0.6% | -$37.2K |
|
480
Carnival Corporation Ltd
CCL
$38.1B
| $5.91M | 0.02% |
582,360
+6,375
| +1% | +$66K |
|
481
CarMax
KMX
$8.13B
| $5.9M | 0.02% |
91,831
+375
| +0.4% | +$25.1K |
|
482
Fox Class A
FOXA
$24.5B
| $5.88M | 0.02% |
172,546
-1,425
| -0.8% | -$48.1K |
|
483
Eastman Chemical
EMN
$8B
| $5.82M | 0.02% |
69,036
+2
| +0% | +$172 |
|
484
Live Nation Entertainment
LYV
$40.5B
| $5.8M | 0.02% |
82,841
+685
| +0.8% | +$50.2K |
|
485
iShares MSCI EAFE ETF
EFA
$78B
| $5.8M | 0.02% |
81,032
+31,614
| +64% | +$2.21M |
|
486
Gen Digital
GEN
$16.4B
| $5.67M | 0.02% |
330,557
-2,869
| -0.9% | -$57.6K |
|
487
Molson Coors Class B
TAP
$7.79B
| $5.65M | 0.02% |
109,248
+1,119
| +1% | +$57.9K |
|
488
Globe Life
GL
$14.2B
| $5.61M | 0.02% |
50,952
-1,077
| -2% | -$126K |
|
489
American Airlines Group
AAL
$10.1B
| $5.58M | 0.02% |
378,102
+4,304
| +1% | +$67.1K |
|
490
Allegion
ALLE
$13.4B
| $5.49M | 0.02% |
51,464
+524
| +1% | +$58.8K |
|
491
Regency Centers
REG
$14.7B
| $5.48M | 0.02% |
89,498
+917
| +1% | +$57.7K |
|
492
Vanguard Information Technology ETF
VGT
$139B
| $5.29M | 0.02% |
109,712
-6,160
| -5% | -$272K |
|
493
Pentair
PNR
$10.4B
| $5.28M | 0.02% |
95,594
+982
| +1% | +$52.2K |
|
494
Pinnacle West Capital
PNW
$12.2B
| $5.21M | 0.02% |
65,749
+674
| +1% | +$50.9K |
|
495
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $5.15M | 0.02% |
39,801
-23,889
| -38% | -$3.12M |
|
496
F5
FFIV
$22.9B
| $5.09M | 0.02% |
34,937
+509
| +1% | +$73.5K |
|
497
Rollins
ROL
$18.3B
| $5.05M | 0.02% |
134,507
+1,858
| +1% | +$67K |
|
498
Robert Half
RHI
$3.87B
| $5.05M | 0.02% |
62,633
+183
| +0.3% | +$14.5K |
|
499
Dentsply Sirona
XRAY
$2.68B
| $4.97M | 0.02% |
126,490
+1,281
| +1% | +$47K |
|
500
Bath & Body Works
BBWI
$4.06B
| $4.9M | 0.02% |
134,060
+1,383
| +1% | +$57.9K |
|
Similar funds
VIA
SAM
Chevy Chase Trust's Q1 2023 Portfolio in Review
As of Q1 2023, Chevy Chase Trust held 664 positions worth $25.3B, up 7.4% from $23.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Chevy Chase Trust's Q1 2023 filing shows 7 new, 437 increased, 146 reduced and 28 closed positions. Its largest new stake was GE HealthCare: 212,346 shares worth $17.4M. The largest sale was Accenture, an estimated $32.7M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
- Chevy Chase Trust's largest Q1 2023 buy was GE HealthCare: 212,346 shares worth $17.4M.
- Chevy Chase Trust added most to Vertex Pharmaceuticals in Q1 2023, an estimated $36.8M increase.
- Chevy Chase Trust's biggest Q1 2023 reduction was Accenture, cutting an estimated $32.7M.
- Chevy Chase Trust fully exited iShares US Telecommunications ETF in Q1 2023, selling an estimated $12.5M.
- Chevy Chase Trust's ten largest holdings make up 27% of its $25.3B portfolio in Q1 2023.
- Chevy Chase Trust opened 7 new positions and closed 28 in Q1 2023.
- Chevy Chase Trust's portfolio value rose 7.4% quarter-over-quarter to $25.3B.
Based on Chevy Chase Trust's 13F filing for Q1 2023, filed 16 May 2023.